Skip to main content
SpringerLink
Log in

ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen

  • Research Article
  • Published:
Tumor Biology

Abstract

Although there have been substantial advances in our knowledge of the resistance of diffuse large B cell lymphoma (DLBCL) to chemotherapy, there are few efficient treatment strategies for recurrent/refractory DLBCL. The aim of this study was to investigate the role of aldehyde dehydrogenase (ALDH) 1A1 in the resistance of diffuse large B cell lymphoma to the chemotherapeutic mixture consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). The involvement of ALDH1A1 in DLBCL was elucidated by knockdown and pharmacologic inhibition; Cell Counting Kit-8 (CCK-8) and clone formation assays were used to determine its role in CHOP sensitivity and clone formation ability. Caspase colorimetric assay was used to measure the extent of apoptosis. Western blot analysis was used to measure signal transducer and activator of transcription 3 (STAT3)/nuclear factor kappa B (NF-κB) signaling proteins, and quantitative real-time PCR (RT-PCR) was used to measure the differential expression of ALDH1A1 of DLBCL patients and healthy donors. ALDH1A1 showed a 5.64-fold higher expression in malignant B cells than in normal B cells. Diethylaminobenzaldehyde (DEAB) decreased the half maximal inhibitory concentration (IC50) of the CHOP regimen in Farage cells from 344.78 ± 65.75 to 183.88 ± 49.75 ng/ml (P = 0.004). Both knockdown and inhibition of ALDH1A1 reduced clonogenicity, increased caspase-3/caspase-9 activity, and attenuated the phosphorylation status of STAT3/NF-κB. The prognosis of patients with a high level of ALDH1A1 expression was poor compared with that of patients with low levels of expression (P = 0.044). ALDH1A1 is a new mediator for resistance of DLBCL to CHOP; it is a predictor of clinical prognosis and may serve as a potential target to improve chemotherapy responsiveness of human DLBCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Maxwell SA, Li Z, Jaye D, Ballard S, Ferrell J, et al. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen. J Biol Chem. 2009;284:22379–89.

    Article  CAS  Google Scholar 

  2. Ikeda J, Mamat S, Tian T, Wang Y, Luo W, et al. Reactive oxygen species and aldehyde dehydrogenase activity in Hodgkin lymphoma cells. Lab Invest. 2012;92:606–14.

    Article  CAS  Google Scholar 

  3. Fujita S, Morii E, Rahadiani N, Wada N, Hori Y, et al. Significance of aldehyde dehydrogenase 1 expression in stromal cells of diffuse large B-cell lymphoma. Exp Ther Med. 2011;2:591–94.

    Article  Google Scholar 

  4. Koppaka V, Thompson DC, Chen Y, Ellermann M, Nicolaou KC, et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol Rev. 2012;64:520–39.

    Article  CAS  Google Scholar 

  5. Liu Y, Zeng L, Zhang S, Zeng S, Huang J. Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods. Med Oncol. 2013;30:528.

    Article  Google Scholar 

  6. Sládek NE, Kollander R, Sreerama L, Kiang DT. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol. 2002;49:309–21.

    Article  Google Scholar 

  7. Moreb JS, Ucar D, Han S, Amory JK, Goldstein AS, et al. The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem Biol Interact. 2012;195:52–60.

    Article  CAS  Google Scholar 

  8. Kahlert C, Gaitzsch E, Steinert G, Mogler C, Herpel E, et al. Expression analysis of aldehyde dehydrogenase 1A1 (ALDH1A1) in colon and rectal cancer in association with prognosis and response to chemotherapy. Ann Surg Oncol. 2012;19:4193–201.

    Article  Google Scholar 

  9. Yang L, Ren Y, Yu X, Qian F, Bian BS, et al. ALDH1A1 defines invasive cancer stem-like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma. Mod Pathol. 2014;27:775–83.

    Article  CAS  Google Scholar 

  10. Xu C, Xie D, Yu SC, Yang XJ, He LR, et al. β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res. 2013;73:3181–9.

    Article  CAS  Google Scholar 

  11. Adam SA, Schnell O, Pöschl J, Eigenbrod S, Kretzschmar HA, et al. ALDH1A1 is a marker of astrocytic differentiation during brain development and correlates with better survival in glioblastoma patients. Brain Pathol. 2012;22:788–97.

    Article  CAS  Google Scholar 

  12. Kahlert C, Bergmann F, Beck J, Welsch T, Mogler C, et al. Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer. BMC Cancer. 2011;11:275.

    Article  CAS  Google Scholar 

  13. Yang S, Yu Y, Jun-Min L, Jian-Qing M, Qiu-Sheng C, et al. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population. Ann Hematol. 2009;88:863–9.

    Article  Google Scholar 

  14. Huang YC, Liu CY, Lu HJ, Liu HT, Hung MH, et al. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era. Ann Hematol. 2013;92:1513–20.

    Article  CAS  Google Scholar 

  15. Miller TP, Dana BW, Weick JK, Jones SE, Coltman CA, et al. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin’s lymphomas. Semin Hematol. 1988;25:17–22.

    CAS  PubMed  Google Scholar 

  16. Sohn SK, Jung JT, Kim DH, Kim JG, Kwak EK, et al. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. Am J Hematol. 2003;73:101–7.

    Article  CAS  Google Scholar 

  17. Zhang B, Zhang Y, Shacter E. Caspase 3-mediated inactivation of rac GTPases promotes drug-induced apoptosis in human lymphoma cells. Mol Cell Biol. 2003;23:5716–25.

    Article  CAS  Google Scholar 

  18. Oudejans JJ, Muris JJ, Meijer CJ. Inhibition of caspase 9 and not caspase 8 mediated apoptosis may determine clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Cell Cycle. 2005;4:526–8.

    Article  CAS  Google Scholar 

  19. Huang X, Meng B, Iqbal J, Ding BB, Perry AM, et al. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2013;31:4520–8.

  20. Bohers E, Mareschal S, Bouzelfen A, Marchand V, Ruminy P, et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Gene Chromosome Cancer. 2014;53:144–53.

  21. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 2009;15:283–93.

    Article  CAS  Google Scholar 

  22. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111:3701–13.

    Article  CAS  Google Scholar 

  23. Ho PL, Kurtova A, Chan KS. Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol. 2012;9:583–94.

    Article  CAS  Google Scholar 

  24. Liu L, Salnikov AV, Bauer N, Aleksandrowicz E, Labsch S, et al. Triptolide reverses hypoxia-induced EMT and stem-like features in pancreatic cancer by NF-κB downregulation. Int J Cancer. 2013;134:2489–503.

    Article  Google Scholar 

  25. Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, et al. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res. 2009;15:6070–8.

    Article  CAS  Google Scholar 

  26. Liu P, Kumar IS, Brown S, Kannappan V, Tawari PE, et al. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br J Cancer. 2013;109:1876–85.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by grants from the Natural Science Foundation of Hunan Province (11JJ3115).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Oncology, Xiangya Hospital, Central South University, 88 Xiangya Road, Changsha, 410008, Hunan, People’s Republic of China

    Ying-hui Song, Mei-zuo Zhong, Ping-ping Gan, You-hong Tang, Yi-ping Liu, Jin-qiong Jiang & Li Li

  2. Department of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China

    Ping-yong Yi

Authors
  1. Ying-hui Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mei-zuo Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ping-ping Gan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ping-yong Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. You-hong Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yi-ping Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jin-qiong Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Li Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mei-zuo Zhong.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Song, Yh., Zhong, Mz., Gan, Pp. et al. ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen. Tumor Biol. 35, 11809–11817 (2014). https://doi.org/10.1007/s13277-014-2335-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2335-9

Keywords

Search

Navigation